[go: up one dir, main page]

WO2008035795A1 - Method for preventing and treating disease with hypochlorous acid - Google Patents

Method for preventing and treating disease with hypochlorous acid Download PDF

Info

Publication number
WO2008035795A1
WO2008035795A1 PCT/JP2007/068595 JP2007068595W WO2008035795A1 WO 2008035795 A1 WO2008035795 A1 WO 2008035795A1 JP 2007068595 W JP2007068595 W JP 2007068595W WO 2008035795 A1 WO2008035795 A1 WO 2008035795A1
Authority
WO
WIPO (PCT)
Prior art keywords
hypochlorous acid
aqueous solution
injection
disease
hypochlorite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/068595
Other languages
French (fr)
Japanese (ja)
Inventor
Toshihisa Gouda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOUDA CO Ltd
Original Assignee
GOUDA CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOUDA CO Ltd filed Critical GOUDA CO Ltd
Publication of WO2008035795A1 publication Critical patent/WO2008035795A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/20Elemental chlorine; Inorganic compounds releasing chlorine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the present invention is an aqueous solution of hypochlorous acid, a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite, which can be produced inexpensively and easily in large quantities, mammals or humans other than humans.
  • the present invention relates to a technique for preventing or treating diseases caused by microorganisms such as viruses, bacteria and the like by administering them into the body by injection, drip infusion or the like. Background art
  • vacciniacin antibiotics, synthetic antibacterial agents and the like have been used for the treatment and prevention of diseases caused by microorganisms such as viruses and bacteria.
  • JP-A-2005 / 075375 discloses hypochlorous acid compositions containing hypochlorous acid and sodium hypochlorite as septic arthritis.
  • a method is disclosed for treating septic arthritis by injecting it into the joint.
  • this method is an injection into a joint without blood vessels, and is not a method for treating or preventing a disease by administering a drug solution to a wide area of the body, spreading, penetrating, or blood circulation.
  • the medicinal solution for injection described in this patent specification is an invention utilizing the pharmacological effect of chlorite ion (C 1 0 2 ), and does not utilize the pharmacological effect of hypochlorous acid. Disclosure of the invention
  • the present invention relates to diseases caused by microorganisms such as viruses, bacteria and the like by administering a substance (aqueous solution) which can be produced inexpensively and easily in large quantities into a mammalian or avian body by injection, infusion or other methods.
  • a substance aqueous solution
  • the task is to provide technology to prevent or treat
  • an aqueous solution of hypochlorous acid or hypochlorous acid having a pH of 4.0 or more and 100 or less, and a free chlorine concentration of 1 mg or more Z kg or more and 1000 mg / kg or less Provides injections and drops that are a mixed aqueous solution of chloric acid and hypochlorite or an aqueous solution of hypochlorite Do.
  • the present invention excludes a person who is easy to spread, permeate, or circulate blood of the injected drug or drip of the present invention to the site of the body necessary for the injected drug or dripping drug S administered, prophylactic or therapeutic.
  • a substance which can be produced inexpensively and easily in large quantities (an aqueous solution of hypochlorous acid, or a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite) Injections or drops) are provided.
  • a disease caused by microorganisms such as viruses, bacteria and the like by administering the injection or drip of the present invention to a predetermined site of a mammal or a bird by injection, infusion or the like.
  • the first aspect of the present invention is: pH 4.0 or more and 10.0 or less, free chlorine concentration is lmg
  • hypochlorous acid or mixed aqueous solution of hypochlorous acid and hypochlorite or an aqueous solution of hypochlorite, or an aqueous solution of hypochlorous acid or an aqueous solution of hypochlorite.
  • hypochlorous acid composition is produced by neutrophils in blood. It was discovered as an oxidant to be produced.
  • the progress of research on medical use and manufacturing methods of hypochlorous acid thereafter is described in Japanese Patent Application Publication No. 2005-2005.
  • Neutrophils are blood cells that account for less than 60% of blood cells excluding red blood cells in the case of human beings, but activated neutrophils are much more potent from hydrogen peroxide to sodium hypochlorite by the Mye mouth peroxidase enzyme. Active production of hypochlorous acid having high bactericidal activity has been clarified, and it is widely known as a known fact.
  • the pH of the injectable drug and the drip agent is pH 4.0 or less, chlorine gas is likely to be generated, and if the pH is 10.0 or more, the tissue at the injection site is easily inflamed. , 4.0 or more 10. 0 or less is desirable.
  • the effective chlorine concentration of injectable and instillable drugs when the effective chlorine concentration is 1 mgZkg or less, the volume of the injectable solution or instilled drug becomes extremely large, and the physiological burden on the animal receiving injection or drip increases excessively.
  • the task of injection or instillation becomes difficult, and if it is 10, 000 mg z kg or more, the site of injection or instillation becomes prone to inflammation, so lmg z kg or more and 10,000 mg Z kg or less preferable.
  • aqueous solution of hypochlorous acid is extremely simple, and the aqueous solution of hypochlorous acid is a saline solution or dilute hydrochloric acid. Can be easily manufactured in large quantities inexpensively by the electrolysis method of
  • sodium hypochlorite which is most widely used, is industrially easily produced in large quantities by absorbing the chlorine gas generated by the electrolysis of sodium chloride into an aqueous solution of sodium hydroxide. It is manufactured.
  • the aqueous solution of hypochlorous acid can be easily produced by adding the acid of a food additive as a pH adjusting agent to an aqueous solution of sodium hypochlorite.
  • the mixed aqueous solution of hypochlorous acid and hypochlorite can be easily produced by mixing an aqueous solution of hypochlorous acid and an aqueous solution of hypochlorite.
  • an aqueous solution of sodium hypochlorite is a safe substance, has long been approved as a food additive, and is widely used for sterilization in the food industry worldwide. It has been revealed that an aqueous solution of hypochlorous acid is a safe substance with much higher bactericidal power than sodium hypochlorite aqueous solution, and it has been approved as a food additive in Japan in 2002 and widely used. It is done.
  • Hypochlorous acid is a substance that exhibits a bactericidal effect as a stronger oxidant than hydrogen peroxide in the body, and is considered to be the most important component in the preventive and therapeutic effects of the present invention.
  • Hypochlorous acid and hypochlorous acid In the case of a mixed aqueous salt solution, hypochlorous acid (HCIO) dissociates in the alkaline region to form hypochlorite ion (CIO-) and hydrogen ion (H +), and hypochlorous acid and hypochlorite ion The ratio between and greatly depends on the pH of the solution.
  • pH 4.0 power such as at least 99% in 5.5, pH95, such as pH 7.0. 9 to 80%, about 60% of pH 7.4 in human blood is hypochlorous acid, and the rest is dissociated into hypochlorite ion and hydrogen ion.
  • about 70% is dissociated into hypochlorite ion and hydrogen ion in the alkaline region of pH 800, and it is about 95% in pH 9.5 and almost 10 0 in pH 9.5 or more. It is dissociated into 0% hypochlorite ion and hydrogen ion.
  • UV-visible absorption methods of wavelengths of 235 nm and 292 nm are known, respectively.
  • the total concentration of hypochlorous acid and hypochlorite ion can be measured by measuring the concentration of free available chlorine, from the correlation between the value measured by the above and the available chlorine concentration.
  • the available chlorine generally hypochlorite, the hypochlorite ion, dissolved chlorine (C 1 2) of the total (free available chlorine) chlorambucil and reacts with ⁇ Pi ammonium compounds in water Min (binding effective chlorine The total amount of).
  • the aqueous solution of hypochlorous acid has a pH value of less than 4.0, chlorine gas is likely to be generated.
  • hypochlorous acid containing no ammonia compound such as pH 4.0 to 10. 0.
  • the total concentration of hypochlorous acid and hypochlorite ion can be approximately known by measuring the effective chlorine concentration. Therefore, the product specifications for the aqueous solution of hypochlorous acid and the mixed aqueous solution of hypochlorous acid and hypochlorite are generally indicated or defined in Japan as mg Z kg of effective chlorine concentration.
  • DPD method effective chlorine measurement method
  • Japan for measuring hypochlorous acid and hypochlorite ion concentration.
  • blood of animals to be injected is used.
  • the amount of injection solution injected as compared to the amount is very small as shown in the later examples, and the animal has a physiological function to keep the pH of blood at a constant value.
  • the pH range of the injection solution is preferably 4.0 to 100.0, preferably 6.0 to 9.0, and most preferably 6.5 to 7.5.
  • the injection or infusion drug of the present invention is administered to a mammal or a bird by injection, infusion or other means to a site which is easily diffused, penetrated, or circulated in the body. It is a method for preventing or treating diseases caused by viruses such as mammalian viruses, bacteria, fungi, protozoa and the like (hereinafter referred to as "the methods of the present invention for preventing or treating").
  • Mammals or birds targeted by the methods of prevention or treatment of the present invention include, but not particularly limited to, domestic animals such as pigs, cows, horses, sheep, goats and chickens, and poultry.
  • the preventive or therapeutic method of the present invention is mammalian or avian virus, bacteria, mold
  • E-Squier disease E-Squier disease
  • h PRR S Breeding pig 'Respiratory disorder (Poor Reproductive and Respiratory Syndrome)
  • PMWS postweaning multisystemic growth syndrome
  • TGE swine infectious gastroenteritis
  • PED swine epidemic diarrhea
  • PRRS is a complex infectious disease, and complex infections such as mycoplasma, circovirus, streptococcus, and pastrella. Symptoms become severe due to
  • the preventive or therapeutic method of the present invention is to administer a prescribed amount of hypochlorous acid injection solution to mammals or birds other than humans by injection, infusion or other methods at a site where it is easy to diffuse, penetrate, or circulate in the body. It is
  • the effective chlorine concentration of the injection solution is lmg / kg to 10, OO Omgzkg, preferably 5mg / kg force, etc. 200mg / kg, most preferably 50mg / kg to 1 000mg / kg It is kg.
  • the most disease-prone time of the pig's lifetime is the so-called weanling piglets from weaning to 70 days of age, when the transfer antibody from sows decreases and it becomes easy to be infected with pathogens in the field. .
  • PRRS is the most frequent, and it is not uncommon for piglet mortality to exceed 30%.
  • Table 1 shows hypochlorous acid injection (P H 6.9), which was prepared by electrolysis of a saline solution, to baby weaned piglets (average body weight at weaning 6 kg) which had moved to the weaning house 25 days after parturition.
  • Test chlorine dose 60 mg / kg (effective chlorine concentration) 2 times no (effective chlorine amount 0.1 2 mg)
  • Table 1 shows comparative piglet mortality data for the target ports. The same injection was carried out every third day after delivery and every 10th day after delivery, even in the A pig farm only, and in the distribution stable.
  • hypochlorous acid injection is much cheaper than vaccines and antibiotics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

It is intended to provide a method for preventing or treating a disease of a mammal or a bird caused by a microorganism such as a virus, a bacterium, a fungus or a protozoan as an inexpensive and simple method without fear of losing its preventive or therapeutic effect due to a viral mutation or a resistant bacterium. In the method, an aqueous solution of hypochlorous acid, which is widely used as a disinfectant in the field of prevention and treatment of diseases, approved as a food additive in the food field, and known to be secreted by neutrophils in the blood with myeloperoxidase enzyme in the medical field is used as an injection.

Description

次亜塩素酸による病気の予防及ぴ治療法 技術分野  Prevention and treatment of diseases caused by hypochlorous acid

本発明は、 安価且つ容易に大量に製造可能な、 次亜塩素酸水溶液、 次亜塩素 酸と次亜塩素酸塩の混合水溶液又は次亜塩素酸塩の水溶液を、 人を除く哺乳動物 又は鳥類の体内に、 注射、 点滴その他の方法で投与することにより、 ウィールス 、 細菌等の微生物に起因する病気の予防或いは治療する技術に関する。 背景技術  The present invention is an aqueous solution of hypochlorous acid, a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite, which can be produced inexpensively and easily in large quantities, mammals or humans other than humans. The present invention relates to a technique for preventing or treating diseases caused by microorganisms such as viruses, bacteria and the like by administering them into the body by injection, drip infusion or the like. Background art

従来、 医学及び獣医学分野では、 ウィールス、 細菌等の微生物に起因する病 気の治療及び予防に対して、 ワク明チンや抗生物質、 合成抗菌剤等が使用されてい る。  Conventionally, in the medical and veterinary medicine fields, vacciniacin, antibiotics, synthetic antibacterial agents and the like have been used for the treatment and prevention of diseases caused by microorganisms such as viruses and bacteria.

しかしながら、 これらのワクチン田や抗生物質、 合成抗菌剤は、 研究開発及び製 造に多額の費用を要する。 また,ワクチンに関しては、 人ィンフルェンザウィール ス用ワクチンで広く知られている如く、 ウイ一ルスが変異するとワクチンの効果 がなくなる場合があるという問題がある。 さらに、 抗生物質や合成抗菌剤に関して は、 広く知られている如く耐性菌の問題がある。  However, these vaccine fields, antibiotics and synthetic antibacterial agents are expensive for research and development and production. In addition, regarding vaccines, as is widely known for human influenza vaccines, there is a problem that when the virus is mutated, the effects of the vaccine may be lost. Furthermore, with regard to antibiotics and synthetic antibacterial agents, there is a problem of resistant bacteria as widely known.

したがって、 安価且つ容易に大量に製造することができ、 しかも、 ウィールス が変異しても継続して使用することができ、 また、 耐性菌が発生する問題の少ない 、 ウィールス、 細菌等の微生物に起因する病気の予防或いは治療する技術の開発が 要望されている。  Therefore, it can be produced inexpensively and easily in large quantities, and can be used continuously even if the virus is mutated, and the problem with few resistant bacteria occurring is caused by microorganisms such as viruses and bacteria. There is a demand for the development of techniques to prevent or treat various diseases.

本発明に関連して、 特表 2 0 0 5 - 5 0 7 3 9 5号公報には、 次亜塩素酸およ ぴ次亜塩素酸ナトリゥムを含有する次亜塩素酸組成物を、 敗血症関節炎の関節内に 注射することにより、 敗血症関節炎を治療する方法が開示されている。  In the context of the present invention, JP-A-2005 / 075375 discloses hypochlorous acid compositions containing hypochlorous acid and sodium hypochlorite as septic arthritis. A method is disclosed for treating septic arthritis by injecting it into the joint.

しかしながら、 この方法は、 血管のない関節内への注射であり、 薬液を体内の 広い範囲に拡散、 浸透、 血液循環し易い部位に投与して病気を治療或いは予防する 方法ではない。  However, this method is an injection into a joint without blood vessels, and is not a method for treating or preventing a disease by administering a drug solution to a wide area of the body, spreading, penetrating, or blood circulation.

また、 特公平 2 _ 3 4 3 2 6号公報には、 亜塩素酸ナトリウム溶液、 次亜塩素 酸ナトリゥム溶液、 クロリル硫酸、 過硼酸ナトリゥム又は過炭酸ナトリウム、 及ぴ 過酸化ナトリゥムを混合 ·反応させて得られる、 感染症を治療するための注射用薬 薬剤成分が開示されている。  Further, in Japanese Patent Publication No. 2 346, a mixture of sodium chlorite solution, sodium hypochlorite solution, chloryl sulfate, sodium perborate or sodium percarbonate, and sodium peroxide are mixed and reacted. An injectable drug component for treating an infectious disease, which is obtainable, is disclosed.

しかしながら、 この特許明細に記載された注射用薬液は、 亜塩素酸イオン (C 1 o 2 ) の薬理効果を利用した発明であって、 次亜塩素酸の薬理効果を利用する ものではない。 発明の開示 However, the medicinal solution for injection described in this patent specification is an invention utilizing the pharmacological effect of chlorite ion (C 1 0 2 ), and does not utilize the pharmacological effect of hypochlorous acid. Disclosure of the invention

( 1 ) 発明が解決しょうとする課題  (1) Problems to be solved by the invention

本発明は、 安価且つ容易に大量に製造可能な物質 (水溶液) を、 哺乳動物又は 鳥類の体内に、 注射、 点滴その他の方法で投与することにより、 ウィールス、 細菌 等の微生物に起因する病気の予防或いは治療する技術を提供することを課題とする  The present invention relates to diseases caused by microorganisms such as viruses, bacteria and the like by administering a substance (aqueous solution) which can be produced inexpensively and easily in large quantities into a mammalian or avian body by injection, infusion or other methods. The task is to provide technology to prevent or treat

( 2 ) 課題を解決するための手段 (2) Means to solve the problem

本発明は第 1に、 p H 4 . 0以上 1 0 . 0以下、 遊離塩素濃度が 1 m g Z k g 以上 1 0, 0 0 0 m g / k g以下の、 次亜塩素酸の水溶液、 又は次亜塩素酸と次亜 塩素酸塩の混合水溶液、 又は次亜塩素酸塩の水溶液である注射薬及ぴ点滴薬を提供 する。 In the present invention, first, an aqueous solution of hypochlorous acid or hypochlorous acid having a pH of 4.0 or more and 100 or less, and a free chlorine concentration of 1 mg or more Z kg or more and 1000 mg / kg or less Provides injections and drops that are a mixed aqueous solution of chloric acid and hypochlorite or an aqueous solution of hypochlorite Do.

本発明は第 2に、 本発明の注射薬又は点滴薬を、 投与した注射薬又は点滴薬 力 S、 予防或いは治療に必要な体内の部位に拡散、 浸透、 血液循環し易い、 人を除 く哺乳動物又は鳥類の任意の部位に、 注射、 点滴その他の方法で投与することに より、 ウィールス及ぴ細菌、 カビ、 原生動物等の微生物に起因する病気の治療或 は予防をする方法を提供する。 発明の効果  Second, the present invention excludes a person who is easy to spread, permeate, or circulate blood of the injected drug or drip of the present invention to the site of the body necessary for the injected drug or dripping drug S administered, prophylactic or therapeutic. Provided is a method for treating or preventing a disease caused by microorganisms such as viruses and bacteria, fungi, protozoa etc. by administration to any part of mammals or birds by injection, infusion or other methods. . Effect of the invention

本発明によれば、 安価且つ容易に大量に製造可能な物質 (次亜塩素酸の水溶液 、 又は次亜塩素酸と次亜塩素酸塩の混合水溶液、 又は次亜塩素酸塩の水溶液からな る注射薬又は点滴薬) が提供される。  According to the present invention, a substance which can be produced inexpensively and easily in large quantities (an aqueous solution of hypochlorous acid, or a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite) Injections or drops) are provided.

また、 本発明によれば、 本発明の注射薬又は点滴薬を、 哺乳動物又は鳥類の所 定部位に、 注射、 点滴その他の方法で投与することにより、 ウィールス、 細菌等の 微生物に起因する病気の予防或いは治療する技術が提供される。 発明を実施するための最良の形態  Further, according to the present invention, a disease caused by microorganisms such as viruses, bacteria and the like by administering the injection or drip of the present invention to a predetermined site of a mammal or a bird by injection, infusion or the like. Techniques for the prevention or treatment of BEST MODE FOR CARRYING OUT THE INVENTION

以下、 本発明を詳細に説明する。  Hereinafter, the present invention will be described in detail.

(1) 本発明の第 1は、 pH4. 0以上 1 0. 0以下、 遊離塩素濃度が lmg (1) The first aspect of the present invention is: pH 4.0 or more and 10.0 or less, free chlorine concentration is lmg

/kg以上 1 0, 00 OmgZk g以下の次亜塩素酸の水溶液、 又は次亜塩素酸と 次亜塩素酸塩の混合水溶液、 又は次亜塩素酸塩の水溶液である注射薬又は点滴薬で ある。 It is an aqueous solution of hypochlorous acid or mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite, or an aqueous solution of hypochlorous acid or an aqueous solution of hypochlorite. .

第一次世界大戦後、 感染症の予防及び治療の為に生物活性物質の研究が広く行 なわれてきたが、 その過程に於いて次亜塩素酸組成物は血液中の好中球によって生 成される酸化剤として発見されたものである。 その後の次亜塩素酸の医療への利用 及び製造方法に関する研究の進展状況は、 特表 2 0 0 5— 5 0 7 3 9 5号公報に記 載されている。  After World War I, research on bioactive substances has been widely carried out for the prevention and treatment of infectious diseases, but in the process, hypochlorous acid composition is produced by neutrophils in blood. It was discovered as an oxidant to be produced. The progress of research on medical use and manufacturing methods of hypochlorous acid thereafter is described in Japanese Patent Application Publication No. 2005-2005.

好中球は人の場合では赤血球を除く血球の 60 %弱を占める血球であるが、 活性化した好中球はミエ口ペルォキシダーゼ酵素によって、 過酸化水素から次亜 塩素酸ナトリゥムょり遥かに強力な殺菌力を持つ次亜塩素酸を活発に産生するこ とが明らかになり、 公知の事実として広く知られている。  Neutrophils are blood cells that account for less than 60% of blood cells excluding red blood cells in the case of human beings, but activated neutrophils are much more potent from hydrogen peroxide to sodium hypochlorite by the Mye mouth peroxidase enzyme. Active production of hypochlorous acid having high bactericidal activity has been clarified, and it is widely known as a known fact.

注射薬及ぴ点滴薬の p Hは、 pHが 4. 0以下であると、 塩素ガスが発生し易 くなり、 pHが 1 0. 0以上では注射した部位の組織が炎症を起こし易くなるので 、 4. 0以上 1 0. 0以下が望ましい。  If the pH of the injectable drug and the drip agent is pH 4.0 or less, chlorine gas is likely to be generated, and if the pH is 10.0 or more, the tissue at the injection site is easily inflamed. , 4.0 or more 10. 0 or less is desirable.

注射薬及び点滴薬の有効塩素濃度に関しては、 有効塩素濃度が 1 mgZk g以 下では注射液又は点滴薬の液量が非常に大きくなり、 注射或いは点滴を受ける動物 の生理的負担が過度に増えて注射或いは点滴の作業が困難になること、 及び又 1 0 , 000 m gZk g以上では、 注射又は点滴した部位に炎症が生じ易くなること から、 lmgZk g以上 1 0, 000 m g Z k g以下が好ましい。  With regard to the effective chlorine concentration of injectable and instillable drugs, when the effective chlorine concentration is 1 mgZkg or less, the volume of the injectable solution or instilled drug becomes extremely large, and the physiological burden on the animal receiving injection or drip increases excessively. The task of injection or instillation becomes difficult, and if it is 10, 000 mg z kg or more, the site of injection or instillation becomes prone to inflammation, so lmg z kg or more and 10,000 mg Z kg or less preferable.

次亜塩素酸水溶液、 次亜塩素酸と次亜塩素酸塩の混合水溶液、 又は次亜塩素酸 塩の水溶液の製造は極めて簡単であり、 次亜塩素酸の水溶液は、 食塩水或いは希塩 酸の電気分解法で安価に簡単に大量に製造することができる。  The preparation of an aqueous solution of hypochlorous acid, a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorous acid salt is extremely simple, and the aqueous solution of hypochlorous acid is a saline solution or dilute hydrochloric acid. Can be easily manufactured in large quantities inexpensively by the electrolysis method of

次亜塩素酸塩の内、 最も広く使用されている次亜塩素酸ナトリウムは、 食塩の 電気分解により発生した塩素ガスを、 水酸化ナトリウムの水溶液に吸収させること により、 工業的に大量に簡単に製造されている。  Among the hypochlorites, sodium hypochlorite, which is most widely used, is industrially easily produced in large quantities by absorbing the chlorine gas generated by the electrolysis of sodium chloride into an aqueous solution of sodium hydroxide. It is manufactured.

次亜塩素酸水溶液は、 次亜塩素酸ナトリゥム水溶液に p H調整剤として食品添 加物の酸を添加することによつても、 容易に製造することが出来る。  The aqueous solution of hypochlorous acid can be easily produced by adding the acid of a food additive as a pH adjusting agent to an aqueous solution of sodium hypochlorite.

次亜塩素酸と次亜塩素酸塩の混合水溶液は、 次亜塩素酸の水溶液と次亜塩素酸塩の 水溶液を混合することによつても、 容易に製造することができる。 また、 次亜塩素酸ナトリ ウムの水溶液は安全な物質であり、 食品添加物として 古くから認可されており、 食品業界では殺菌に世界的に広く使用されている。 次亜 塩素酸の水溶液は次亜塩素酸ソーダ水溶液より遥かに強力な殺菌力をもつ安全な物 質であることが解明され、 日本では 2 0 0 2年に食品添加物として認可され広く使 用されている。 The mixed aqueous solution of hypochlorous acid and hypochlorite can be easily produced by mixing an aqueous solution of hypochlorous acid and an aqueous solution of hypochlorite. In addition, an aqueous solution of sodium hypochlorite is a safe substance, has long been approved as a food additive, and is widely used for sterilization in the food industry worldwide. It has been revealed that an aqueous solution of hypochlorous acid is a safe substance with much higher bactericidal power than sodium hypochlorite aqueous solution, and it has been approved as a food additive in Japan in 2002 and widely used. It is done.

次亜塩素酸は、 体内では過酸化水素より強力なォキシダントとして殺菌効果を 示す物質であり、 本発明の予防治療効果上最も重要な成分と考えられるが、 次亜塩 素酸と次亜塩素酸塩の混合水溶液の場合に、 次亜塩素酸 (H C I O ) はアルカリ領 域では解離して次亜塩酸イオン (C I O— ) と水素イオン (H + ) となり、 次亜塩 素酸と次亜塩酸イオンとの比率は、 溶液の p Hによって大きく変わる。  Hypochlorous acid is a substance that exhibits a bactericidal effect as a stronger oxidant than hydrogen peroxide in the body, and is considered to be the most important component in the preventive and therapeutic effects of the present invention. Hypochlorous acid and hypochlorous acid In the case of a mixed aqueous salt solution, hypochlorous acid (HCIO) dissociates in the alkaline region to form hypochlorite ion (CIO-) and hydrogen ion (H +), and hypochlorous acid and hypochlorite ion The ratio between and greatly depends on the pH of the solution.

例えば、 次亜塩素酸と次亜塩素酸ナトリウムの常温の混合水溶液の場合、 p H 4 . 0力、ら 5 . 5では 9 9 %以上、 p H 5 . 5力、ら 7 . 0では 9 9 %から 8 0 %、 人の血液の p H 7 . 4では約 6 0 %が次亜塩素酸であり、 残りが次亜塩素酸イオン と水素イオンに解離している。 逆にアルカリ領域の p H 8 . 0では約 7 0 %が次亜 塩素酸イオンと水素イオンに解離しおり、 p H 9 . 0では約 9 5 %、 p H 9 . 5以 では,ほぼ 1 0 0 %次亜塩素酸イオンと水素イオンに解離している。  For example, in the case of a mixed aqueous solution of hypochlorous acid and sodium hypochlorite at room temperature, pH 4.0 power, such as at least 99% in 5.5, pH95, such as pH 7.0. 9 to 80%, about 60% of pH 7.4 in human blood is hypochlorous acid, and the rest is dissociated into hypochlorite ion and hydrogen ion. On the contrary, about 70% is dissociated into hypochlorite ion and hydrogen ion in the alkaline region of pH 800, and it is about 95% in pH 9.5 and almost 10 0 in pH 9.5 or more. It is dissociated into 0% hypochlorite ion and hydrogen ion.

次亜塩素酸の濃度の分析法及び次亜塩素酸イオン濃度の分析法としては、 それ ぞれ波長 2 3 5 n m及び 2 9 2 n mの紫外可視吸光法が知られているが、 この分析 方法による測定値と有効塩素濃度との相関から、 次亜塩素酸及び次亜塩素酸イオン の合計濃度は遊離有効塩素濃度を測定することにより測定が可能である。  As a method of analyzing the concentration of hypochlorous acid and a method of analyzing the concentration of hypochlorite ion, UV-visible absorption methods of wavelengths of 235 nm and 292 nm are known, respectively. The total concentration of hypochlorous acid and hypochlorite ion can be measured by measuring the concentration of free available chlorine, from the correlation between the value measured by the above and the available chlorine concentration.

有効塩素とは、 一般には次亜塩素酸, 次亜塩素酸イオン、 溶存塩素 (C 1 2 ) の総量 (遊離有効塩素) 及ぴ水中のアンモニア化合物と反応して生成したクロラ ミン (結合有効塩素) の総量である。 しかし、 次亜塩素酸水溶液は p Hが 4 . 0 以下であると塩素ガスが発生しやすくなるが、 アンモニア化合物を含まない p H 4 . 0から 1 0 . ◦の次亜塩素酸, 次亜塩素酸イオン或は両者の混合物の水溶液 では、 有効塩素濃度を測定すれば、 次亜塩素酸と次亜塩素酸イオンの合計濃度を 近似的に知ることができる。 従って、 次亜塩素酸の水溶液及ぴ次亜塩素酸と次亜塩 素酸塩の混合水溶液の製品規格は、 日本では一般に有効塩素濃度 m g Z k gをもつ て表示し或いは規定している。 The available chlorine generally hypochlorite, the hypochlorite ion, dissolved chlorine (C 1 2) of the total (free available chlorine) chlorambucil and reacts with及Pi ammonium compounds in water Min (binding effective chlorine The total amount of). However, if the aqueous solution of hypochlorous acid has a pH value of less than 4.0, chlorine gas is likely to be generated. However, hypochlorous acid containing no ammonia compound, such as pH 4.0 to 10. 0. In an aqueous solution of chlorate ion or a mixture of both, the total concentration of hypochlorous acid and hypochlorite ion can be approximately known by measuring the effective chlorine concentration. Therefore, the product specifications for the aqueous solution of hypochlorous acid and the mixed aqueous solution of hypochlorous acid and hypochlorite are generally indicated or defined in Japan as mg Z kg of effective chlorine concentration.

有効塩素濃度の測定方法は簡単であるので、 日本では次亜塩素酸及び次亜塩素 酸イオンの濃度測定には D P D法と呼ばれる有効塩素測定法が広く用いられている 一般に、 注射する動物の血液量に比較して注射する注射液の量は、 後の実施例 で示す如く極めて僅かであり、 又動物には血液の p Hを一定の値に保つ生理機能が ある。 従って、 注射液の p Hが血液の p Hより高く、 次亜塩素酸が大部分次亜塩素 酸イオンと水素イオンに解離していても、 注射液が血液中に浸透混合拡散した段 階では、 注射液中の次亜塩素酸、 次亜塩素酸イオン、 及ぴ水素イオンは、 血液の p H 、 温度、 溶存物質に対応する解離状態に解離度が減少して、 次亜塩素酸の強 い殺菌力を発揮することになると考えられる。 しかしながら、 注射液の p Hの範 囲は 4 . 0から 1 0 . 0、 望ましくは 6 . 0から 9 . 0、 最も望ましくは 6 . 5 から 7 . 5が良い。  Because the method of measuring effective chlorine concentration is simple, effective chlorine measurement method called DPD method is widely used in Japan for measuring hypochlorous acid and hypochlorite ion concentration. Generally, blood of animals to be injected is used. The amount of injection solution injected as compared to the amount is very small as shown in the later examples, and the animal has a physiological function to keep the pH of blood at a constant value. Therefore, even if the pH of the injection solution is higher than the pH of blood, and hypochlorous acid is mostly dissociated into hypochlorous acid ions and hydrogen ions, in the stage where the injection solution permeates and diffuses into the blood, Hypochlorous acid, hypochlorite ion, and hydrogen ion in the injection solution decrease the degree of dissociation to the corresponding state of pH, temperature, and dissolved substances in blood, and the hypochlorous acid It is believed that it will exert a great sterilizing power. However, the pH range of the injection solution is preferably 4.0 to 100.0, preferably 6.0 to 9.0, and most preferably 6.5 to 7.5.

( 2 ) 本発明の第 2は、 本発明の注射薬又は点滴薬を、 哺乳動物又は鳥類に、 体内に拡散、 浸透、 血液循環し易い部位に注射、 点滴その他の方法で投与すること により、 哺乳動物のウィールス或いは細菌、 カビ、 原生動物等の微生物による病気 の予防又は治療を行なう方法 (以下、 「本発明の予防又は治療方法」 と略記) であ る。  (2) In the second aspect of the present invention, the injection or infusion drug of the present invention is administered to a mammal or a bird by injection, infusion or other means to a site which is easily diffused, penetrated, or circulated in the body. It is a method for preventing or treating diseases caused by viruses such as mammalian viruses, bacteria, fungi, protozoa and the like (hereinafter referred to as "the methods of the present invention for preventing or treating").

本発明の予防又は治療方法の対象とする哺乳動物又は鳥類としては、 特に制限 されないが、 豚、 牛、 馬、 羊、 山羊、 鶏などの家畜、 家禽類が挙げられる。 本発明の予防又は治療方は、 哺乳類又は鳥類の、 ウィールス或いは細菌、 カビMammals or birds targeted by the methods of prevention or treatment of the present invention include, but not particularly limited to, domestic animals such as pigs, cows, horses, sheep, goats and chickens, and poultry. The preventive or therapeutic method of the present invention is mammalian or avian virus, bacteria, mold

、 原生動物等の微生物による病気であれば、 特に制限されない。 以下、 養豚場の 豚を例にとり、 豚のウィールス及び細菌等微生物に起因する病気の予防治療技術を 以下に説明する。 There are no particular restrictions on the disease caused by microorganisms such as protozoa. In the following, taking piglets in a pig farm as an example, techniques for preventing and treating diseases caused by microorganisms such as virus and bacteria are explained below.

豚にはウイ一ルスに起因する病気として、 ォーエスキー病 (AD) 、 繁殖豚 ' 呼吸器障著症候 (Porcine Reproductive and Respiratory Syndrome 以" h PRR Sと略記) 、 日本脳炎、 豚パルボウイルス病、 豚ェンテロウィルス病、 豚ィ ンフルェンザ、 離乳後多臓器性発育不良症候群 (PMWS) 、 豚伝染性胃腸炎 (T GE) 、 豚流行性下痢 (P ED) 、 豚コレラ、 豚痘、 口蹄疫等約 1 5種類の病気が める。  Diseases caused by viruses in swine: E-Squier disease (AD), Breeding pig 'Respiratory disorder (Poor Reproductive and Respiratory Syndrome) (abbreviated as h PRR S), Japanese encephalitis, porcine parvovirus disease, swine Enterovirus disease, swine fluenza, postweaning multisystemic growth syndrome (PMWS), swine infectious gastroenteritis (TGE), swine epidemic diarrhea (PED), swine fever, swine fever, foot disease, etc. There are 5 types of illness.

また豚の細菌による病気としては、 丹毒、 レブトスビラ病、 サルモネラ病、 連 鎖球菌病、 大腸菌病、 壊死性腸炎、 グレーサー病、 マイコプラズマ病、 萎縮性鼻炎 (AR) 、 すす病、 豚胸膜肺炎、 パスッレラ病、 豚赤痢、 炭疽、 破傷風等約 1 8種 類の病気がある。  In addition, as diseases caused by bacteria of swine, erysipelas, rickets virus, salmonella disease, streptococcal disease, coliform disease, necrotizing enteritis, grazer disease, mycoplasmal disease, atrophic rhinitis (AR), soot disease, swine pleura pneumonia, pasilella There are about 18 kinds of diseases such as sickness, swine dysentery, anthrax and tetanus.

豚の病気では、 P RR Sの発生頻度が最も高く、 その対策が重要視されている 病気である。 1 9 9 0年代前半に PRR Sウイ一ルスが日本国内で始めて確認され 、 様々な対策が採られてきたが、 その対策は困難を極めている。  Among swine diseases, it is the disease with the highest frequency of occurrence of P RR S and the measures for which are regarded as important. In the early 1990s, PRRS virus was first confirmed in Japan, and various measures have been taken, but the measures are extremely difficult.

豚が PRR Sウイ一ルスに単独感染しても、 それだけでは重篤な症状にならな いが、 P R R Sは複合感染病であって、 マイコプラズマ、 サーコウィールス、 ス ト レプトコッカス、 パスッレラなどの複合感染により症状が重篤になる。  If a pig is infected with PRRS virus alone, it does not become a serious symptom, but PRRS is a complex infectious disease, and complex infections such as mycoplasma, circovirus, streptococcus, and pastrella. Symptoms become severe due to

本発明の予防又は治療方法は、 次亜塩素酸注射液の所定量を、 人を除く哺乳動 物又は鳥類に、 体内に拡散、 浸透、 血液循環し易い部位に注射、 点滴その他の方法 で投与するものである。  The preventive or therapeutic method of the present invention is to administer a prescribed amount of hypochlorous acid injection solution to mammals or birds other than humans by injection, infusion or other methods at a site where it is easy to diffuse, penetrate, or circulate in the body. It is

注射、 点滴以外のその他の投与方法としては、 皮膚から圧力により薬液を、 「 針なし注射器」 を用いて体内に浸透させる方法があり、 畜産業界では採用している 所もある。  As other administration methods other than injection and infusion, there is a method of permeating the drug solution from the skin by pressure using a "needleless syringe", and there are places adopted by the livestock industry.

注射液の有効塩素濃度は、 l mg/k gから 1 0, O O OmgZk g、 望まし くは 5mg/k g力、ら 2, 0 00m g/k g、 最も望ましくは 5 0mg/k gから 1 000 m g/k gである。 実施例  The effective chlorine concentration of the injection solution is lmg / kg to 10, OO Omgzkg, preferably 5mg / kg force, etc. 200mg / kg, most preferably 50mg / kg to 1 000mg / kg It is kg. Example

以下、 本発明を豚の病気の中で最も発生頻度の高い PRR S病について、 分娩子豚 と離乳子豚を対象に実施した例を示す。 ただし、 本発明は以下の実施例に何ら制限 されるものではなレ、。 Hereinafter, the present invention will be described with respect to the most frequently occurring PRR S disease among swine diseases, in which examples are carried out on delivery piglets and weaned piglets. However, the present invention is in no way limited to the following examples.

豚の一生のなかで一番病気にかかり易い時期は、 母豚からの移行抗体が減少し 、 野外の病原体に感染し易くなる離乳から 70日齢位までの、 いわゆる離乳期の子 豚である。 特に離乳期にかかる病気としては PRR Sが最も多く、 子豚の死亡率が 30 %を越える場合も珍しくない。  The most disease-prone time of the pig's lifetime is the so-called weanling piglets from weaning to 70 days of age, when the transfer antibody from sows decreases and it becomes easy to be infected with pathogens in the field. . Especially for diseases affecting the weaning period, PRRS is the most frequent, and it is not uncommon for piglet mortality to exceed 30%.

第 1表に、 分娩後 2 5日で離乳舎に移動した離乳子豚 (離乳時の平均体重 6 k g) に、 食塩水の電解で製造した次亜塩素酸注射液 (p H 6. 9、 有効塩素濃度 6 0mg/k g) を 2m lノ回 (有効塩素量 0. 1 2 m g ) づっ、 子豚の頸部に 1週 間 1回ずつ 5回注射した試験口ットと注射をしなかった対象口ットの、 子豚の死亡 率の比較データを表 1に示す。 伹し、 A養豚場のみ、 分娩舎に於いても、 分娩後 3 日目、 1 0日目、 2 0目毎に、 同じ注射をおこなった。 分 娩 舎 離 乳 舎 Table 1 shows hypochlorous acid injection (P H 6.9), which was prepared by electrolysis of a saline solution, to baby weaned piglets (average body weight at weaning 6 kg) which had moved to the weaning house 25 days after parturition. Test chlorine dose of 60 mg / kg (effective chlorine concentration) 2 times no (effective chlorine amount 0.1 2 mg) Based on the test mouth injected with 5 injections once a week into the neck of a piglet and no injection Table 1 shows comparative piglet mortality data for the target ports. The same injection was carried out every third day after delivery and every 10th day after delivery, even in the A pig farm only, and in the distribution stable. Distribution house

p\ (翁  p \ (翁

養豚場 Πッ卜  Pig farm

分娩 2 5日令 4 5日令 1 0 0日令 終|ひ^ Q · 区分 死亡率 7 0曰令 死亡率  Delivery 2 5th Dec. 4 5th Dec. 1st Dec. 10th Dec. End * Category · Mortality rate 7 0 Decrease Mortality

子豚数 子豚数 子豚数 子豚数  Piglet number Piglet number Piglet number Piglet number

子豚数 死亡率 ① ② ① ② ③ ④ ④ /② ④ ① 非注射 231 211 12% 188 166 160 24% 31% Piglet number Mortality rate 1 2 1 2 3 4 4/2 4 1 No injection 231 211 12% 188 166 160 24% 31%

A A

注射 238 228 4% 220 210 203 11% 15% 非注射 29 28 4% 24 19 18 36% 38% Injection 238 228 4% 220 210 203 11% 15% Not injected 29 28 4 4 24 19 18 36% 38%

B B

注射 30 29 4% 27 26 26 10% 13% 非注射 34 33 3% 29 28 27 18% 21% Injection 30 29 4% 27 26 26 10% 13% Not injected 34 33 3 3% 29 28 27 18% 21%

C C

注射 33 33 0% 31 31 30 9% 9% 非注射 38 33 3% 33 31 31 6% 18% Injected 33 33 0% 31 31 30 9% 9% Not injected 38 33 3 3 33 31 31 6% 18%

D D

注射 37 37 0% 35 34 34 8% 8% 非注射 46 44 5% 33 31 31 30% 33% Injection 37 37 0% 35 34 34 8% 8% Not injected 46 44 5% 33 31 31 30% 33%

E E

注射 47 46 2% 44 42 42 9% 11% 第 1表より、 離乳子豚の離乳後の死亡率は平均で 2 3 %から 9 %へ減少し、 ま た総合死亡率は平均で 2 8 %から 1 1 %に低下しており、 大きな効果があることは 明瞭である。 産業上の利用可能性 本発明には下記の三つの効果があり、 産業上の利用価値の高いものである。 Injections 47 46 2% 44 42 42 9% 11% From Table 1, mortality after weaning of weaned piglets decreased on average from 23% to 9% and overall mortality on average 28% It is clearly reduced to 11%, and it is clear that there is a big effect. Industrial Applicability The present invention has the following three effects, and has high industrial application value.

① 哺乳動物又は鳥類に感染するウィールス及び細菌等の微生物による病気の発生 予防及ぴ治療、 死亡率の低下に大きな効果がある。 (1) It has a great effect on prevention and treatment of diseases caused by microorganisms such as viruses and bacteria that infect mammals or birds, and reduction of mortality.

② ワクチンや抗生物質等と異なり、 ウイ一ルスの変異や耐性菌に起因する問題が ない。  2 Unlike vaccines and antibiotics, there are no problems caused by virus mutations or resistant bacteria.

③ 次亜塩素酸注射薬の製造コス トは、 ワクチンや抗生物質などに比較して遥かに 安価である。  The manufacturing cost of hypochlorous acid injection is much cheaper than vaccines and antibiotics.

Claims

請 求 の 範 囲 The scope of the claims 1 · 病気の予防或いは治療に必要な体内の部位に拡散、 浸透、 血液循環し易い任意の 部位に注射又は点滴に使用する為の、 ρΗ4. 0以上 1 0. 0以下、 有効塩素濃 度が lmgZk g以上 1 0, O O OmgZk g以下の、 次亜塩素酸の水溶液、 又 は次亜塩素酸と次亜塩素酸塩の混合水溶液、 又は次亜塩素酸塩の水溶液からなる 注射薬及び点滴薬。 1 · Η 以上 4.0 or more and 10. 0 or less, effective chlorine concentration, for use in injection or infusion in any area that is easy to spread, penetrate, or circulate in the body necessary for the prevention or treatment of a disease Injections and drops consisting of an aqueous solution of hypochlorous acid, a mixed aqueous solution of hypochlorous acid and hypochlorite, or an aqueous solution of hypochlorite, of lmgZk g to 100, OO Omgzk g or less . 2. 請求 1の注射薬又は点滴薬を、 投与した注射薬が、 病気の予防或いは治療に必要 な体内の部位に拡散、 浸透、 血液循環し易い、 人を除く哺乳動物又は鳥類の任意 の部位に、 注射、 点滴その他の方法で投与することにより、 ウィールス及び細菌 、 カビ、 原生動物等の微生物に起因する病気の治療或いは予防をする方法。 2. Any part of mammals or birds other than humans that are easy to spread, penetrate, and circulate blood in the area of the body required for the prevention or treatment of a disease in which the injection or drip of claim 1 was administered. A method for treating or preventing a disease caused by microorganisms such as viruses and bacteria, molds and protozoa by administering them by injection, infusion or the like. 3. 豚の病気を対象とする請求 2に記載する方法。 :3. A method according to claim 2 which targets pig disease. : 4. 豚繁殖 ·呼吸障害症候群 (Porcine Reproductive and Respiratory Syndrome) を対象とする請求 2に記載する方法。 4. A method according to claim 2, which is directed to Porcine Reproductive and Respiratory Syndrome.
PCT/JP2007/068595 2006-09-21 2007-09-18 Method for preventing and treating disease with hypochlorous acid Ceased WO2008035795A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-255263 2006-09-21
JP2006255263A JP2008195612A (en) 2006-09-21 2006-09-21 Method for preventing and treating disease with hypochlorous acid

Publications (1)

Publication Number Publication Date
WO2008035795A1 true WO2008035795A1 (en) 2008-03-27

Family

ID=39200616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/068595 Ceased WO2008035795A1 (en) 2006-09-21 2007-09-18 Method for preventing and treating disease with hypochlorous acid

Country Status (2)

Country Link
JP (1) JP2008195612A (en)
WO (1) WO2008035795A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189757A1 (en) * 2015-05-22 2016-12-01 株式会社 東芝 Space sterilization device and space deodorization device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511752A (en) * 1994-07-15 1997-11-25 メディカル・ディスカバリーズ・インコーポレーテッド Electrohydrolyzed saline as an in vivo microbicide for the treatment of cardiomyopathy and multiple sclerosis
JP2005507395A (en) * 2001-10-01 2005-03-17 アキラブス・エスエイ Hypochlorous acid composition and use thereof
JP2005075752A (en) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science Vaccine preparation for swine reproduction / respiratory disorder syndrome
RU2251423C1 (en) * 2003-10-06 2005-05-10 Федеральное государственное образовательное учреждение высшего профессионального образования Чувашский государственный университет им. И.Н. Ульянова Method for intravenous infusion of sodium hypochlorite
RU2275921C2 (en) * 2004-02-04 2006-05-10 Роман Геннадиевич Мязин Method for treating chronic diffuse hepatic diseases due to applying the course of intravenous injections of sodium hypochlorite solutions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511752A (en) * 1994-07-15 1997-11-25 メディカル・ディスカバリーズ・インコーポレーテッド Electrohydrolyzed saline as an in vivo microbicide for the treatment of cardiomyopathy and multiple sclerosis
JP2005507395A (en) * 2001-10-01 2005-03-17 アキラブス・エスエイ Hypochlorous acid composition and use thereof
JP2005075752A (en) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science Vaccine preparation for swine reproduction / respiratory disorder syndrome
RU2251423C1 (en) * 2003-10-06 2005-05-10 Федеральное государственное образовательное учреждение высшего профессионального образования Чувашский государственный университет им. И.Н. Ульянова Method for intravenous infusion of sodium hypochlorite
RU2275921C2 (en) * 2004-02-04 2006-05-10 Роман Геннадиевич Мязин Method for treating chronic diffuse hepatic diseases due to applying the course of intravenous injections of sodium hypochlorite solutions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189757A1 (en) * 2015-05-22 2016-12-01 株式会社 東芝 Space sterilization device and space deodorization device
JPWO2016189757A1 (en) * 2015-05-22 2017-11-30 株式会社東芝 Spatial sterilization device and spatial deodorization device

Also Published As

Publication number Publication date
JP2008195612A (en) 2008-08-28

Similar Documents

Publication Publication Date Title
CN102480972B (en) Solutions containing hypochlorous acid and methods of use thereof
BR112013026491B1 (en) INTRAMAMMARY INFUSION RELEASE DEVICE
KR20090009442A (en) Bactericidal and virucidal composition with improved bactericidal power
CN101278896A (en) Chitosan nano silver gel agent and uses thereof
RU2414902C1 (en) Bactericidal composition for prevention and treatment of infectious diseases of hoofs in animals
CN110037940A (en) A kind of sterilizing oral disinfection mouthwash and preparation method thereof and application method
CN102008399B (en) Preparation method of antimicrobial mouthwash
CN105263489B (en) Antimicrobial composition and method of making the same
US20220110968A1 (en) Compositions and methods to disinfect, treat and prevent microbial infections
CN104524559A (en) Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof
CN103907598A (en) Chlorine disinfectant effervescent tablet
US20240016834A1 (en) Antimicrobial agent composition and manufacturing method and product thereof
WO2008035795A1 (en) Method for preventing and treating disease with hypochlorous acid
CN107582737A (en) A kind of compound chlorohexidene oral-cavity disinfectant and preparation method thereof
CN101755763A (en) Disinfection composition for preventing and treating livestock and poultry breeding diseases and prepration method and application thereof
CN101972271B (en) Chlorine dioxide mucous membrane gel and preparation method thereof
US20220008456A1 (en) Compositions and methods to disinfect, treat and prevent microbial infections
CN101023753A (en) Oxidation-type disinfecting sterilizing agent and preparing method
RU2145499C1 (en) Preparation gastropulmin for treatment and prophylaxis of gastro-enteric and respiratory sicknesses in newborn calves and lambs
TWI848607B (en) Use of a hypochlorous acid composition for preparing a pharmaceutical composition for preventing, improving or treating radiation dermatitis
CN114073685B (en) Application of cresol in drugs for treating coronavirus infectious diseases
CN101132778A (en) Composition for regulating water quality of water for administration of water disinfectant sensitive drugs or vaccines
JP2002020297A (en) Oral adsorbed carbon preparation
CN115804754A (en) Morphine nasal spray and preparation method thereof
US20210401876A1 (en) Pharmaceutical composition of chlorine for treatment of respiratory viral infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07807862

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07807862

Country of ref document: EP

Kind code of ref document: A1